MCM
IBB icon

MAI Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

MAI Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-400
Closed -$60K – 821
2021
Q1 		$60K Buy
+400
New +$63.5K ﹤0.01% 708

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

MAI Capital Management's IBB Position: Q2 2026 in Review

MAI Capital Management increased its iShares Biotechnology ETF (IBB) stake by 5.9% in Q2 2026, buying an estimated $837K and bringing the position to 86,701 shares worth $16.5M. The position accounts for 0.06% of the portfolio, ranked #243.

MAI Capital Management first reported a position in IBB in Q2 2015 and has held it in 36 quarters since. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • MAI Capital Management held 86,701 shares of iShares Biotechnology ETF worth $16.5M as of Q2 2026.
  • MAI Capital Management bought 4,869 iShares Biotechnology ETF shares in Q2 2026, an estimated $837K.
  • iShares Biotechnology ETF made up 0.06% of MAI Capital Management's portfolio in Q2 2026, its #243 holding.
  • MAI Capital Management first reported a position in iShares Biotechnology ETF in Q2 2015 and has held it in 36 quarters since.
  • 960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.